Iptacopan is in development for the treatment of patients with complement 3 glomerulopathy (C3G) which is a rare disease. C3 is a blood protein that plays a key role in the normal immunity. The damaging build-up of the C3 protein in kidneys of patients with C3 glomerulopathy mostly results from dysregulation of the alternative complement pathway which is part of the body's immune system. The build-up of this C3 protein damages the kidneys and can lead to a life-threatening condition which prevents the kidneys from filtering fluids and waste products from the body.
Iptacopan for treating complement 3 glomerulopathy
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Partners-Industry_Motifs_Motifs_Conduction-broadcasting_RGB-scaled_edited_1233.jpg)
Iptacopan is in development for the treatment of patients with complement 3 glomerulopathy (C3G) which is a rare disease.